{
    "Clinical Trial ID": "NCT00375427",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Zoledronic Acid Every 3 Months",
        "  Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.",
        "INTERVENTION 2: ",
        "  Zoledronic Acid Every 4 Weeks",
        "  Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions."
    ],
    "Eligibility": [
        "Inclusion criteria:",
        "  Female patients  18 years of age.",
        "  Written informed consent given.",
        "  Histologically confirmed Stage IV breast cancer with at least one bone metastasis radiologically confirmed.",
        "  Previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months.",
        "  Eastern Cooperative Oncology Group (ECOG) performance status 2 .",
        "  Life expectancy  1 year.",
        "Exclusion criteria:",
        "  More than 3 months since last infusion of Zoledronic Acid (Zometa\u00ae).",
        "  Treatments with other bisphosphonate than Zoledronic Acid (Zometa\u00ae) at any time prior to study entry.",
        "  Serum creatinine > 3 mg/dL (265 \u03bcmol/L) or calculated (Cockcroft-Gault formula) creatinine clearance (CLCr) < 30 mL/min CrCl = ({[140-age (years)] x weight(kg)}/ [72 x serum creatinine (mg/dL)])x 0.85",
        "  Corrected (adjusted for serum albumin) serum calcium < 8 mg/dl (2 mmol/L) or > 12 mg/dL ( 3.0 mmol/L).",
        "  Current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.",
        "  Recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants).",
        "  Pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. Women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide).",
        "  History of non-compliance to medical regimens or potential unreliable behavior.",
        "  Known sensitivity to study drug(s) or class of study drug(s).",
        "  Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study",
        "  Use of any other investigational agent in the last 30 days."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Annual Overall Skeletal Morbidity Rate (SMR)",
        "  The SMR was computed by summing all Skeletal Related Event(s) (SREs)which occurred during the observation period and dividing it by the ratio \"days of observation period / 365.25\", for each participant. SRE was defined as: pathologic bone fracture, spinal cord compression, surgery to bone both curative and prophylactic, radiation therapy to bone, or hypercalcemia of malignancy.",
        "  SMR (years) = 365.25 x SMR(days) where SMR (days) = total number of SREs / total SRE risk period (days). Risk period for SMR was computed as the days from randomization date to the date of last visit.",
        "  Time frame: 12 months",
        "Results 1: ",
        "  Arm/Group Title: Zoledronic Acid Every 3 Months",
        "  Arm/Group Description: Zoledronic acid given as a 15-minute (at least) i.v. infusion every three months. The dose of study drug was the same as administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized participants received a maximum of 4 infusions in this group.",
        "  Overall Number of Participants Analyzed: 209",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Number of Skeletal Events per Year  0.26         (0.81)",
        "Results 2: ",
        "  Arm/Group Title: Zoledronic Acid Every 4 Weeks",
        "  Arm/Group Description: Zoledronic acid given as a 15-minute (at least) i.v. infusion every 4 weeks. The dose of study drug was the as same administered before study entry; that is, 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Participants randomized to this group received up to 12 infusions.",
        "  Overall Number of Participants Analyzed: 216",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Number of Skeletal Events per Year  0.22         (0.57)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 21/209 (10.05%)",
        "  Anaemia 0/209 (0.00%)",
        "  Febrile neutropenia 0/209 (0.00%)",
        "  Thrombocytopenia 0/209 (0.00%)",
        "  Acute myocardial infarction 0/209 (0.00%)",
        "  Cardiac failure 0/209 (0.00%)",
        "  Diplopia 0/209 (0.00%)",
        "  Gastric haemorrhage 0/209 (0.00%)",
        "  Nausea 0/209 (0.00%)",
        "  Oral pain 0/209 (0.00%)",
        "  Vomiting 1/209 (0.48%)",
        "  Mucosal inflammation 0/209 (0.00%)",
        "  Pain 1/209 (0.48%)",
        "Adverse Events 2:",
        "  Total: 29/216 (13.43%)",
        "  Anaemia 2/216 (0.93%)",
        "  Febrile neutropenia 2/216 (0.93%)",
        "  Thrombocytopenia 2/216 (0.93%)",
        "  Acute myocardial infarction 1/216 (0.46%)",
        "  Cardiac failure 1/216 (0.46%)",
        "  Diplopia 1/216 (0.46%)",
        "  Gastric haemorrhage 1/216 (0.46%)",
        "  Nausea 1/216 (0.46%)",
        "  Oral pain 2/216 (0.93%)",
        "  Vomiting 2/216 (0.93%)",
        "  Mucosal inflammation 1/216 (0.46%)",
        "  Pain 0/216 (0.00%)"
    ]
}